Creative Biolabs: ADC Development Solutions Got Refreshed

By: Get News
Creative Biolabs, leveraging front technologies and a deep understanding of bioconjugation chemistry, continues to drive innovation in the field of antibody-drug conjugate (ADC) development, offering cutting-edge solutions to address unmet research needs.

New York, USA - February 19, 2024 - The latest release by UCLA Health about an ADC's clinical trial recruitment has once again rippled across the cancer research community. ADCs stand as a revolutionary approach for disease therapies, especially breast cancer, which leverage the outstanding targetability of antibodies and exert therapeutic effects once internalized. As an expert in bioconjugation chemistry, Creative Biolabs pioneers ADC design and production, providing prominent solutions for bioconjugation, characterization techniques, and cytotoxicity detection.

Creative Biolabs' strengths manifest in its one-stop ADC development pipeline that encapsulates antibody, linker, and payload screening, chemical conjugation, and analysis.

"The workflow of developing an ADC is classical," according to a scientist at Creative Biolabs, "and our specialties are the tremendous experience gained from the numorous antibody projects we've been through, all sorts of conjugation options, and ADC analysis sets far more comprehensive than any peers' in the industry."

Employing various quantification assays like ELISA and LC-MS, Creative Biolabs can assess critical pharmacokinetic parameters such as drug-to-antibody ratio (DAR), tissue distribution, and ADC metabolism and clearance. These ADC characterization techniques ensure the production of high-quality candidates that meet and exceed industry standards, ultimately facilitating their successful translation into clinical applications.

In addition to PK profile validation, Creative Biolabs offers advanced ADC cytotoxicity detection tests to evaluate the potency of conjugate candidates in vitro. Based on a large collection of tumor cell lines, Creative Biolabs conducts the first qualitative evaluation of the drug efficacy of an ADC in terms of cell viability, cell apoptosis, cell cycle status, etc., thereby providing a baseline for ADC improvement and a guideline for downstream process designs.

"Our commitment to providing this versatile ADC development service stems from our dedication to advancing targeted therapies and our will to resolve researchers' project needs in a one-stop manner," said the scientist. "By bridging the gap between scientific expertise and industry demands, we can empower researchers and pharmaceutical companies to translate groundbreaking ideas into transformative therapies."

With its relentless focus on scientific excellence and innovation, Creative Biolabs continues to revolutionize ADC development and has scheduled to participate in the World ADC San Diego in 2024 to exchange ideas with practitioners worldwide.

For more information, please visit


Creative Biolabs is a global leading custom service provider in the field of ADC production and engineering, whose products and services are widely used in academic research and pharmaceutical development applications. With advanced platforms, seasoned scientists, and extensive project experience, Creative Biolabs has successfully helped global scientists and pharmaceutical companies achieve success in their pursuit of novel conjugate drugs.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.